An analyst sees good growth prospects for Immunic Inc (IMUX)

With 0.58 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.72 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.2800 whereas the lowest price it dropped to was $1.2100. The 52-week range on IMUX shows that it touched its highest point at $3.11 and its lowest point at $0.95 during that stretch. It currently has a 1-year price target of $13.75. Beta for the stock currently stands at 2.04.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Price Performance and Earnings:

The stock lost -45.54% in the past year, while it has lost -18.67% so far this year. A look at the trailing 12-month EPS for IMUX yields -3.26 with Next year EPS estimates of -1.68. For the next quarter, that number is -0.51. This implies an EPS growth rate of 43.32% for this year and 21.59% for next year. EPS is expected to grow by 15.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 40.88%.


Float and Shares Shorts:

At present, 89.93 million IMUX shares are outstanding with a float of 83.17 million shares on hand for trading. On Jan 31, 2024, short shares totaled 2.59 million, which was 2.88% higher than short shares on Dec 29, 2023. In addition to MUX as the firm’s McEwen Mining Inc., IAUX serves as its i-80 Gold Corp..

Institutional Ownership:

Through their ownership of 60.30% of IMUX’s outstanding shares, institutional investors have majority control over the company.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMUX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMUX analysts setting a high price target of $28.00 and a low target of $5.00, the average target price over the next 12 months is $13.75. Based on these targets, IMUX could surge 2195.08% to reach the target high and rise by 309.84% to reach the target low. Reaching the average price target will result in a growth of 1027.05% from current levels.

Summary of Insider Activity:

Insiders traded IMUX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 5,000 while 0 shares were sold.